鼻咽癌同步放化疗前后炎性指标变化及预测价值

doi:10.6040/j.issn.1673-3770.0.2020.053

摘要/Abstract

摘要： 目的探讨局部晚期鼻咽癌同步放化疗前后外周血中性粒细胞与淋巴细胞比(NLR)和血小板与淋巴细胞比(PLR)的变化及对鼻咽癌复发的预测作用。方法回顾性分析初诊为局部晚期鼻咽癌并行同步放化疗229例患者病历资料,记录同步放化疗前后患者的中性粒细胞、血小板和淋巴细胞值,计算相应的NLR和PLR、ΔNLR和ΔPLR,使用受试者工作特征曲线(ROC),确定NLR和PLR、ΔNLR和ΔPLR的最佳临界值,并根据最佳临界值将ΔNLR和ΔPLR分别分为高低水平两组;使用Cox风险模型分析和Kaplan-Meier分析确定肿瘤复发的独立危险因素以及ΔNLR和ΔPLR对生存的影响。结果以肿瘤复发为结果,NLR和PLR、ΔNLR和ΔPLR的ROC曲线下面积(AUC)分别为0.680、0.678、0.854和0.730, 最佳临界值分别为2.730、135.550、4.982和122.553;单因素分析显示:T分期、N分期、临床分期、诱导/辅助化疗史NLR、PLR、ΔNLR、ΔPLR为鼻咽癌复发的相关因素,进一步行多因素分析提示T分期、N分期、ΔNLR、ΔPLR是鼻咽癌复发的独立危险因素;生存分析显示,ΔHNLR和ΔHPLR组的2年无复发生存率均低于ΔLNLR和ΔLPLR组(ΔHNLR vs. ΔLNLR=0.488 vs. 0.993;ΔHPLR vs. ΔLPLR=0.476 vs. 0.935),ΔHNLR和ΔHPLR组的中位无复发生存时间均为23个月。结论局部晚期鼻咽癌患者的NLR和PLR总体水平在同步放化疗后有所增加,治疗前后NLR和PLR差值越大肿瘤预后越差,且ΔNLR和ΔPLR可作为肿瘤复发的预测指标。

关键词: 鼻咽癌, 同步放化疗, 中性粒细胞与淋巴细胞比, 血小板与淋巴细胞比, 复发

Abstract: Objective To investigate the effect of the neutrophil-lymphocyte ratio(NLR)and platelet-lymphocyte ratio(PLR)in peripheral blood on the prognosis of nasopharyngeal carcinoma(NPC)before and after concurrent chemoradiotherapy. Methods Pre-/post-treatment and changes in neutrophil, platelet, and lymphocyte levels of 229 patients who were diagnosed with locally advanced NPC and received concurrent chemoradiotherapy in Renmin Hospital of Wuhan University were retrospectively analyzed. A receiver operating characteristic(ROC)analysis was performed to determine the optimal cutoff values of NLR, PLR, ΔNLR, and ΔPLR, and the patients were then divided into lower and higher groups according to the optimal cutoff values of ΔNLR and ΔPLR. A Kaplan-Meier analysis and Cox risk model were used to identify independent predictors of recurrence and prognosis. Results The areas under the ROC curve of PLR, NLR, ΔNLR, and ΔPLR in the diagnosis of tumor recurrence were 0.680, 0.678, 0.854, and 0.730, respectively, and the optimal cut-off values for each parameter were 2.730, 135.550, 4.982, and 122.553, respectively. Univariate analysis showed that TNM stages, clinical stages, PLR and NLR, ΔNLR, and ΔPLR were correlated with the recurrence of NPC, whereas the Cox regression model suggested that TNM stages, ΔNLR, and ΔPLR were independent risk factors for the recurrence of NPC. Kaplan-Meier analysis found that the 2-year recurrence-free survival rates of the ΔHNLR and ΔHPLR groups were lower than those of the ΔLNLR and ΔLPLR groups(ΔHNLR vs. ΔLNLR=0.488 vs. 0.993; ΔHPLR vs. ΔLPLR=0.476 vs. 0.935), and that the median recurrence-free survival time for both the ΔHNLR and ΔHPLR groups was 23 months. Conclusion Both NLR and PLR in patients with locally advanced NPC increased after concurrent chemoradiotherapy, and poorer prognosis was correlated with higher ΔNLR and ΔPLR values. Therefore, ΔNLR and ΔPLR can be used to assess risk for tumor recurrence in patients with locally advanced NPC.

Key words: Nasopharyngeal carcinoma, Concurrent chemoradiotherapy, Neutrophil-lymphocyte ratio, Platelet-lymphocyte ratio, Recurrence

中图分类号:

R739.6

范黎,黎越,徐细明. 鼻咽癌同步放化疗前后炎性指标变化及预测价值[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 36-41.

FAN Li, LI Yue, XU Ximing. Changes in and prognostic value of the inflammatory index before and after concurrent chemoradiotherapy for nasopharyngeal carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(6): 36-41.

参考文献

[1] Shalapour S, Karin M. Pas de deux: control of anti-tumor immunity by cancer-associated inflammation[J]. Immunity, 2019, 51(1): 15-26. doi:10.1016/j.immuni.2019.06.021.
[2] Dolan RD, Laird BJA, Klepstad P, et al. An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer[J]. Medicine(Baltimore), 2019, 98(37): e17019. doi:10.1097/MD.0000000000017019.
[3] Derer A, Frey B, Fietkau R, et al. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors[J]. Cancer Immunol Immunother, 2016, 65(7): 779-786. doi:10.1007/s00262-015-1771-8.
[4] Chajon E, Castelli J, Marsiglia H, et al. The synergistic effect of radiotherapy and immunotherapy: a promising but not simple partnership[J]. Crit Rev Oncol, 2017, 111: 124-132. doi:10.1016/j.critrevonc.2017.01.017.
[5] Toulany M. Targeting DNA double-strand break repair pathways to improve radiotherapy response[J]. Genes(Basel), 2019, 10(1): E25. doi:10.3390/genes10010025.
[6] Ma YT, Pitt JM, Li QQ, et al. The renaissance of anti-neoplastic immunity from tumor cell demise[J]. Immunol Rev, 2017, 280(1): 194-206. doi:10.1111/imr.12586.
[7] Lumniczky K, Sáfrány G. The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences[J]. Cancer Lett, 2015, 356(1): 114-125. doi:10.1016/j.canlet.2013.08.024.
[8] Candéias SM, Testard I. The many interactions between the innate immune system and the response to radiation[J]. Cancer Lett, 2015, 368(2): 173-178. doi:10.1016/j.canlet.2015.02.007.
[9] Murata M. Inflammation and cancer[J]. Environ Health Prev Med, 2018, 23(1): 50. doi:10.1186/s12199-018-0740-1.
[10] Shalapour S, Lin XJ, Bastian IN, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity[J]. Nature, 2017, 551(7680): 340-345. doi:10.1038/nature24302.
[11] Dolan RD, McSorley ST, Horgan PG, et al. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2017, 116: 134-146. doi:10.1016/j.critrevonc.2017.06.002.
[12] Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis[J]. Ann Surg Oncol, 2016, 23(2): 646-654. doi:10.1245/s10434-015-4869-5.
[13] Zhao Z, Zhao XR, Lu JJ, et al. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies[J]. Arch Gynecol Obstet, 2018, 297(4): 849-857. doi:10.1007/s00404-018-4678-8.
[14] Lorente L. New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma[J]. World J Gastroenterol, 2018, 24(37): 4230-4242. doi:10.3748/wjg.v24.i37.4230.
[15] Rossi S, Basso M, Strippoli A, et al. Are markers of systemic inflammation good prognostic indicators in colorectal cancer?[J]. Clin Colorectal Cancer, 2017, 16(4): 264-274. doi:10.1016/j.clcc.2017.03.015. 019, 26(1): 31-47. doi:10.1111/iju.13801.
[16] Ohno Y. Role of systemic inflammatory response markers in urological malignancy[J]. International journal of urology: official journal of the Japanese Urological Association,2019,26(1):31-47. doi: 10.1111/iju.13801.
[17] Su L, Zhang MW, Zhang WJ, et al. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis[J]. Medicine(Baltimore), 2017, 96(11): e6364. doi:10.1097/MD.0000000000006364.
[18] Sridharan V, Margalit DN, Lynch SA, et al. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer[J]. Br J Cancer, 2016, 115(2):252-260. doi: 10.1038/bjc.2016.166.
[19] Burnette BC, Liang H, Lee Y, et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity[J]. Cancer Res. 2011, 71(7):2488-2496. doi: 10.1158/0008-5472.CAN-10-2820.
[20] Chen J, Cao Y, Markelc B, et al. Type Ⅰ IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation[J]. I Clin Invest, 2019, 129(10):4224-4238. doi: 10.1172/JCI127458.
[21] Schuler PJ, Harasymczuk M, Schilling B, et al. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer[J]. Clin Cancer Res, 2013, 19(23):6585-6596. doi: 10.1158/1078-0432.CCR-13-0900.
[22] Al-Taei S, Banner R, Powell N, et al. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy[J]. Cancer Immunol Immunother, 2013, 62(12):1821-1830.
[23] van Meir H, Nout RA, Welters MJP, et al. Impact of(chemo)radiotherapy on immune cell composition and function in cervical cancer patients[J]. Oncoimmunology, 2017,6(2):e1267095. doi: 10.1080/2162402X.2016.1267095.
[24] Wennerberg E, Lhuillier C, Vanpouille-Box C, et al. Barriers to radiation-induced In situ tumor vaccination[J]. Front Immunol, 2017, 8: 229. doi:10.3389/fimmu.2017.00229.
[25] Menon H, Ramapriyan R, Cushman TR, et al. Role of radiation therapy in modulation of the tumor stroma and microenvironment[J]. Front Immunol, 2019, 10: 193. doi:10.3389/fimmu.2019.00193.
[26] Wang H, Jiang H, van De Gucht M, et al. Hypoxic radioresistance: can ROS be the key to overcome it?[J]. Cancers(Basel), 2019, 11(1): E112. doi:10.3390/cancers11010112.
[27] Rückert M, Deloch L, Fietkau R, et al. Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies[J]. Strahlenther Onkol, 2018, 194(6): 509-519. doi:10.1007/s00066-018-1287-1.
[28] McLaren PJ, Bronson NW, Hart KD, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios can predict treatment response to neoadjuvant therapy in esophageal cancer[J]. J Gastrointest Surg, 2017, 21(4): 607-613. doi:10.1007/s11605-016-3351-4.
[29] Stöth M, Freire Valls A, Chen MY, et al. Splenectomy reduces lung metastases and tumoral and metastatic niche inflammation[J]. Int J Cancer, 2019, 145(9): 2509-2520. doi:10.1002/ijc.32378.
[30] Ocana A, Nieto-Jiménez C, Pandiella A, et al. Neutrophils in cancer: prognostic role and therapeutic strategies[J]. Mol Cancer, 2017, 16(1): 137. doi:10.1186/s12943-017-0707-7.
[31] Pucci F, Rickelt S, Newton AP, et al. PF4 promotes platelet production and lung cancer growth[J]. Cell Rep, 2016, 17(7): 1764-1772. doi:10.1016/j.celrep.2016.10.031.
[32] Ménétrier-Caux C, Ray-Coquard I, Blay JY, et al. Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines?[J]. J Immunother Cancer, 2019, 7(1): 85. doi:10.1186/s40425-019-0549-5.

相关文章 15

[1]	林小雪,林葆睿,李佩珊,卢标清. 电子鼻咽镜联合窄带成像技术在鼻咽癌中医辨证中的应用[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 40-46.
[2]	刘南仙,杨泽垠,韩琳,张爱英,赵宇亮,薛静,孙怡君,邵永良. 视频脑电图在儿童复发性眩晕诊断中的意义[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 20-25.
[3]	王盛,李银丹,杨金姬. microRNA在鼻咽癌中的作用及其研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 125-131.
[4]	邱前辉,肖旭平,杨钦泰,叶菁,邓泽义,王德生,谭国林,蒋卫红,卢永田,唐隽,石照辉,邓晓聪,刘遗斌,王跃武,段传志,杜德坤,白小欣,陈文伙,莫立根,蔡楚伟,曾鹏,何旭英,杨一梅,赵洲洋,陈健龙,赵充,林志雄,李先明,李曙平,陈冬平,陈勇,黄莹,陈春燕,韩非,黄理金,瞿申红. 鼻咽癌治疗后并发颈动脉爆裂综合征的临床处理专家共识[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 1-18.
[5]	王思权,朱洪申,张晓斌,赵洲洋,马跃,杨一梅,黄理金. 放射治疗后鼻咽癌患者单侧颈内动脉栓塞术后脑卒中及颅神经麻痹的相关因素分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 19-25.
[6]	黄巧,任毅,侯涛,廖行伟,朱子昂,詹晓琳,刘盈,尹时华. 鼻咽癌组织中EphB2表达及与临床病理特征的相关性[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 26-30.
[7]	孙春晓,王文晴,岳田,刘济生. 高低累积顺铂剂量同步放化疗治疗鼻咽癌的疗效分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 31-41.
[8]	徐飞,朱光熹,王可心. 基于决策树算法构建鼻咽癌患者放疗后发生放射性口腔黏膜炎风险的预测模型[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 42-48.
[9]	王再兴,唐志元,李定波,石照辉,曾宪海,张秋航. 鼻咽癌放疗后肿瘤复发及颅底骨坏死引起颈内动脉破裂的治疗方案[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 49-58.
[10]	孙芳,谢楚波,邱前辉. 营养指标对鼻咽癌放射性颅底坏死患者创面修复影响的回顾性分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 59-68.
[11]	朱瑞楷,吴家荣,孙芳,谢楚波,邱前辉. 基于计算机断层扫描血管造影术评估鼻咽癌放疗后引起颈内动脉狭窄状况及其影响因素的研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 77-84.
[12]	覃德波,薛建成,杨文月,胡兵,陈涛,俞艳萍,孟庆国,孙焕吉,苗北平,卢永田. 鼻咽癌诊疗变革:生物标志物与鼻内镜手术协同推进早期治疗发展[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 85-92.
[13]	吴家荣,邱前辉. 颅底筋膜组织在早期复发性鼻咽癌内镜手术中的临床意义[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 108-113.
[14]	杨鸣,刘雪霞,张华. m6A识别蛋白IGF2BPs家族在头颈肿瘤中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 153-161.
[15]	吴敏,李正阳,孟杰,叶惠平. 程序性细胞死亡的分子机制和其在鼻咽癌中的作用[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 152-157.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed